Lupus nephritis: where are we now?
Lightstone
Liz
L
Imperial College Kidney and Transplant Institute, Imperial College London, and West London Renal and Transplant Centre, Hammersmith Hospital, London, UK. l.lightstone@imperial.ac.uk
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001706:Biopsy / Q000592:standards; D004359:Drug Therapy, Combination / Q000379:methods / Q000639:trends; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D000069283:Rituximab; D013256:Steroids / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D013256:Steroids; D000069283:Rituximab; D009173:Mycophenolic Acid; D016559:Tacrolimus